Tumor-Associated Proteolytic Factors uPA and PAI-1: Critical Appraisal of Their Clinical Relevance in Breast Cancer and Their Integration into Decision-Support Algorithms

REFERENCES

• Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 1998; 13: 893–906
   PubMed Web of Science ®Google Scholar
• Andreasen P A, Egelund R, Petersen H H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25–40
   PubMed Web of Science ®Google Scholar
• Preissner K T, Kanse S M, May A E. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000; 12: 621–628
   PubMedGoogle Scholar
• Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932–943
   PubMed Web of Science ®Google Scholar
• Rosenberg S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective. Curr Pharm Des 2003; 9: 4p, (abst.)
   PubMed Web of Science ®Google Scholar
• Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, Magdolen V. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003; 9: 1529–1543
   PubMed Web of Science ®Google Scholar
• Rosenberg S. New developments in the urokinase-type plasminogen activator system. Expert Opin Ther Targets 2001; 5: 711–722
   PubMedGoogle Scholar
• Stefansson S, McMahon G A, Petitclerc E, Lawrence D A. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003; 9: 1545–1564
   PubMed Web of Science ®Google Scholar
• Andreasen P A, Kjoller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1–22
   PubMed Web of Science ®Google Scholar
• Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285–296
   PubMed Web of Science ®Google Scholar
• Schmitt M, Wilhelm O G, Reuning U, Krüger A, Harbeck N, Lengyel E, Graeff H, Gänsbacher B, Kessler H, Bürgle M, Stürzebecher J, Sperl S, Magdolen V. The plasminogen activation system as a novel target for therapeutic strategies. Fibrinolysis 2000; 14: 114–132
   Google Scholar
• Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep C G, Selbmann H K, Graeff H, Schmitt M, for the German Chemo N0Study Group. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913–920
   PubMed Web of Science ®Google Scholar
• Look M P, van Putten W L, Duffy M J, Harbeck N, Brünner N, Kates R, Fernö M, Eppenberger S, Spyratos F, Thomssen C, Sweep C GJ, Peyrat J P, Martin P M, Blankenstein M A, Magdelenat H, Quillien-Pouvreau V, Daver, Ricolleau G, Daxenbichler G, Cufer T, Bendahl P O, Lisboa B, Ulm K, Christensen I J, Meijer-van Gelder M E, Fiets E, Manders P, Broët P, Romain S, Windbichler G, Borstnar S, Beex L VRM, Jänicke F, Klijn J GM, Eppenberger U, Schmitt M, Foekens J A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116–128
   PubMed Web of Science ®Google Scholar
• Harbeck N, Kates R E, Look M P, Meijer-van Gelder M E, Klijn J GM, Jänicke F, Krüger A, Kiechle M, Schmitt M, Foekens J A. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002; 62: 4617–4622
   PubMed Web of Science ®Google Scholar
• Harbeck N, Kates R E, Schmitt M, Gauger K, Kiechle M, Jänicke F, Thomssen C, Look M P, Foekens J A. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 2004; 5: 348–352
   PubMedGoogle Scholar
• Schmitt M, Harbeck N, Daidone M G, Brünner N, Duffy M J, Foekens J A, Sweep F CGJ. Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: Tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int J Oncol 2004; 25: 1397–1406
   PubMed Web of Science ®Google Scholar
• Harbeck N, Kates R E, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M. Urokinase-type plasminogen activator uPA and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thrombosis Haemostasis 2004; 91: 450–456
   PubMed Web of Science ®Google Scholar
• Duffy M J, O'Grady P, Devaney D, O'Siorain L, Fennelly J J, Lijnen H J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 531–533
   PubMed Web of Science ®Google Scholar
• Jänicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989; 2: 1049
   PubMed Web of Science ®Google Scholar
• Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69–78
   Google Scholar
• Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991; 17: 303–312
   PubMed Web of Science ®Google Scholar
• Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24: 195–208
   PubMed Web of Science ®Google Scholar
• Foekens J A, Schmitt M, van Putten W L, Peters H A, Kramer M D, Jänicke F, Klijn J GM. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648–1658
   PubMed Web of Science ®Google Scholar
• Grondahl-Hansen J, Peters H A, van Putten W L, Look M P, Pappot H, Ronne E, Dano K, Klijn J G, Brunner N, Foekens J A. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079–1087
   PubMed Web of Science ®Google Scholar
• Ferno M, Bendahl P O, Borg A, Brundell J, Hirschberg L, Olsson H, Killander D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996; 32A: 793–801
   PubMed Web of Science ®Google Scholar
• Eppenberger U, Kueng W, Schlaeppi J M, Roesel J L, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens J A, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16: 3129–3136
   PubMed Web of Science ®Google Scholar
• Kim S J, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998; 4: 177–182
   PubMed Web of Science ®Google Scholar
• Kute T E, Grondahl-Hansen J, Shao S M, Long R, Russell G, Brünner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998; 47: 9–16
   PubMed Web of Science ®Google Scholar
• Knoop A, Andreasen P A, Andersen J A, Hansen S, Laenkholm A V, Simonsen A C, Andersen J, Overgaard J, Rose C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77: 932–940
   PubMed Web of Science ®Google Scholar
• Bouchet C, Hacene K, Martin P M, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17: 3048–3057
   PubMed Web of Science ®Google Scholar
• Foekens J A, Peters H A, Look M P, Portengen H, Schmitt M, Kramer M D, Brunner N, Janicke F, Meijer-van Gelder M E, Henzen-Logmans S C, van Putten W L, Klijn J G. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636–643
   PubMed Web of Science ®Google Scholar
• Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001; 2448–2457
   PubMed Web of Science ®Google Scholar
• Cufer T, Borstnar S, Vrhovec I. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 2003; 18: 106–115
   PubMed Web of Science ®Google Scholar
• Hansen S, Overgaard J, Rose C, Knoop A, Laenkholm A V, Andersen J, Sorensen F B, Andreasen P A. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer 2003; 88: 102–108
   PubMed Web of Science ®Google Scholar
• Zemzoum I, Kates R E, Ross J S, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022–1028
   PubMed Web of Science ®Google Scholar
• Bouchet C, Ferrero-Pous M, Hacene K, Becette V, Spyratos F. Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma. Int J Biol Markers. 2003; 18: 207–217
   PubMed Web of Science ®Google Scholar
• Manders P, Tjan-Heijnen V C, Span P N, Grebenchtchikov N, Geurts-Moespot A, van Tienoven D T, Beex L V, Sweep F C. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer 2004; 101: 486–494
   PubMed Web of Science ®Google Scholar
• Meo S, Dittadi R, Peloso L, Gion M. The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer. Int J Biol Markers 2004; 19: 282–288
   PubMed Web of Science ®Google Scholar
• Harbeck N, Kates R E, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000–1007
   PubMed Web of Science ®Google Scholar
• Hayes D F, Bast R, Desch C E, Fritsche H, Jr, Kemeny N E, Jessup J M, Locker G Y, Macdonald J S, Mennel R G, Norton L, Ravdin P, Taube S, Winn R J. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456–1466
   PubMed Web of Science ®Google Scholar
• Harbeck N, Thomssen C, Berger U, Ulm K, Kates R, Höfler H, Jänicke F, Graeff H, Schmitt M. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999; 54: 147–157
   PubMed Web of Science ®Google Scholar
• Harbeck N, Meisner C, Prechtl A, Untch M, Selbmann H K, Sweep C GJ, Graeff H, Schmitt M, Jänicke F, Thomssen C, for the German Chemo-N0Study Group. Level-I evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N0 therapy trial. Breast Cancer Res Treat 2001; 69: 213
   Web of Science ®Google Scholar
• Look M, van Putten W, Duffy M, Harbeck N, Christensen I J, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep C GJ, Ulm K, Peyrat J P, Martin P M, Magdelenat H, Brünner N, Duggan C, Lisboa B, Bendahl P O, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder M E, Manders P, Fiets E, Blankenstein M A, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex L VRM, Klijn J GM, Eppenberger U, Jänicke F, Schmitt M, Foekens J A. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 2003; 90: 538–548
   PubMed Web of Science ®Google Scholar
• Sweep C G, Geurts-Moespot J, Grebenschikov N, de Witte J H, Heuvel J J, Schmitt M, Duffy M J, Janicke F, Kramer M D, Foekens J A, Brunner N, Brugal G, Pedersen A N, Benraad T J. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998; 78: 1434–1441
   PubMed Web of Science ®Google Scholar
• Sweep F C, Fritsche H A, Gion M, Klee G G, Schmitt M. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. Int J Oncol 2003; 23: 1715–1726
   PubMed Web of Science ®Google Scholar
• Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527–2530
   PubMed Web of Science ®Google Scholar
• Schmitt M, Lienert S, Prechtel D, Sedlaczek E, Welk A, Reuning U, Magdolen V, Jänicke F, Sweep C GJ, Harbeck N. The urokinase protease system as a target for breast cancer prognosis and therapy: technical considerations. Journal of Clinical Ligand Assay 2002; 25: 43–52
   Google Scholar
• Schmitt M, Sturmheit A S, Welk A, Schnelldorfer C, Harbeck N. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods Mol Med 2006; 120: 245–265
   PubMedGoogle Scholar
• Harbeck N, Alt U, Krüger A, Berger U, Thomssen C, Jänicke F, Kates R, Schmitt M. Prognostic impact of proteolytic factors (uPA, PAI-1, cathepsins B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757–2764
   PubMed Web of Science ®Google Scholar
• Harbeck N, Schmitt M, Kates R E, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Clinical utility of uPA/PAI-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002; 3: 196–200
   PubMedGoogle Scholar
• Manders P, Tjan-Heijnen V C, Span P N, Grebenchtchikov N, Foekens J A, Beex L VAM, Sweep C GJ. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res 2004; 64: 659–664
   PubMed Web of Science ®Google Scholar
• Foekens J A, Look M P, Peters H A, van Putten W L, Portengen H, Klijn J G. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 17(87)751–756
   Google Scholar
• Meijer-van Gelder M E, Look M P, Peters H A, Schmitt M, Brunner N, Harbeck N, Klijn J G, Foekens J A. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 2004; 64: 4563–4568
   PubMed Web of Science ®Google Scholar
• Manders P, Tjan-Heijnen V C, Span P N, Grebenchtchikov N, Geurts-Moespot A J, van Tienoven D T, Beex L VAM, Sweep C GJ. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer. Thromb Haemost 2004; 9: 514–521
   Google Scholar
• Goldhirsch A, Glick J H, Gelber R D, Coates A S, Thurlimann B, Senn H J. Panel Members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–1583
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717
   PubMed Web of Science ®Google Scholar
• Ravdin P M, Siminoff L A, Davis G J, Mercer M B, Hewlett J, Gerson N, Parker H L. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980–991
   PubMed Web of Science ®Google Scholar
• Olivotto I A, Bajdik C D, Ravdin P M, Speers C H, Coldman A J, Norris B D, Davis G J, Chia S K, Gelmon K A. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716–2725
   PubMed Web of Science ®Google Scholar
• Kates R, Harbeck N, Ulm K, Graeff H, Schmitt M. Progress in decision support and forecasting in breast cancer using likelihood-based neural network analysis. Breast Cancer Res Treat 1999; 57: 42, (abst.)
   Google Scholar
• Ravdin P M, Siminoff I A, Harvey J A. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998; 16: 515–521
   PubMed Web of Science ®Google Scholar
• van't Veer L J, Paik S, Hayes D F. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005; 23: 1631–1635
   PubMed Web of Science ®Google Scholar
• Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N. (alle Autoren) Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumors. Exp Opin Biol Ther 2001; 1: 683–691
   PubMed Web of Science ®Google Scholar
• Setyono-Han B, Sturzebecher J, Schmalix W A, Muehlenweg B, Sieuwerts A M, Timmermans M, Magdolen V, Schmitt M, Klijn J G, Foekens J A. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 2005; 93: 779–786
   PubMed Web of Science ®Google Scholar
• Kates R, Schmitt M, Harbeck N. Advanced statistical methods for the definition of new staging models. Recent Results Cancer Res 2003; 162: 101–113
   PubMedGoogle Scholar
• Elston C W, Ellis I O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–410
   PubMed Web of Science ®Google Scholar
• Liestol K, Anderson P, Anderson U. Survival analysis and neural nets. Stat Med 1994; 13: 1189–1120
   PubMed Web of Science ®Google Scholar
• Faraggi D, Simon R. A neural network model for survival data. Stat Med 1995; 14: 73–82
   PubMed Web of Science ®Google Scholar
• Biganzoli E, Boracchi P, Mariani L, Marubini E. Feed forward neural networks for the analysis of censored survival data: A partial logistic regression approach. Stat. Med. 1998; 17: 1169
   PubMed Web of Science ®Google Scholar
• Hornberger J, Cosler L, Lyman G. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node–negative, estrogen-receptor–positive, early-stage breast cancer. Am J Managed Care 2005; 11: 313–324
   PubMed Web of Science ®Google Scholar
• Schumacher M, Rossner R, Vach W. Neural Networks and logistic regression: Part I. Comp Stat Data Analysis 1996; 21: 661–682
   Web of Science ®Google Scholar
• Vach W, Rossner R, Schumacher M. Neural networks and logistic regression: Part II. Comp Stat Data Analysis 1996; 21: 683–701
   Web of Science ®Google Scholar
• Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792
   PubMed Web of Science ®Google Scholar